Test ixekizumab and stopping it in plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult older than 21 years
- A dermatologist has diagnosed you with plaque-type psoriasis
- Your psoriasis is moderate to severe (PASI score at least 12, and IGA at least 3)
- Your psoriasis covers at least 10% of your body surface area
- You are a candidate for light therapy (phototherapy) and/or internal (systemic) treatment
- You can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study is testing how well a new medication called Xeligekimab works in real-life settings for people with moderate to severe plaque psoriasis. It may help if you are starting this treatment for the first time and want to contribute to learning more about its effects.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.